The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

Through the Arkansas Opioid Recovery Partnership, we have funded innovative programs aimed to slow the relentless increase in ...

Palghar: The Union health ministry has stopped operations and production of Aveo Pharmaceuticals Ltd. (Aveo) following ...

Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say ...

Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...

Health care providers can now administer Sublocade subcutaneously into the thigh, buttock, or the back of the upper arm, in addition to the abdomen.

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid ...